Cargando…

Adoring ADAURA: can we cure lung cancer that harbors an EGFR mutation?

Detalles Bibliográficos
Autor principal:	Melosky, Barbara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413026/ https://www.ncbi.nlm.nih.gov/pubmed/37577323 http://dx.doi.org/10.21037/tlcr-23-222

Ejemplares similares

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
por: Ortega-Franco, Ana, et al.
Publicado: (2022)

ADAURA update: only the end of the beginning
por: Muthusamy, Bharathi, et al.
Publicado: (2023)

Can we cure metastatic EGFR-mutated lung cancer today?
por: Christopoulos, Petros
Publicado: (2023)

Could We Have Improved on ADAURA? Refining Global Research Practices to Reduce Cancer Care Disparities
por: West, Howard (Jack), et al.
Publicado: (2023)

Postoperative management for non-small cell lung cancer harboring EGFR mutations
por: Tanaka, Fumihiro, et al.
Publicado: (2020)

God and the Doctor We Alike Adore
por: Duffield, Geo.
Publicado: (1897)

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
por: Zhang, Shannon S, et al.
Publicado: (2022)

Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA
por: Tsuboi, Masahiro, et al.
Publicado: (2021)

EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
por: Le, Xiuning, et al.
Publicado: (2023)

Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?
por: Kanemura, Hiroaki, et al.
Publicado: (2020)

Adorate deum Gregorian chant from the Proper of the Mass.
Publicado: (1993)

La adorable pecadora Let's make love /
Publicado: (2002)

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
por: Herbst, Roy S., et al.
Publicado: (2023)

Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?
por: Tanzawa, Shigeru, et al.
Publicado: (2019)

Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report
por: Kuwata, Taiji, et al.
Publicado: (2016)

Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold!
por: Fiorelli, Alfonso, et al.
Publicado: (2020)

Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer
por: Shepherd, Annemarie F., et al.
Publicado: (2020)

Mechanochemically assisted hydrolysis in the ADOR process
por: Rainer, Daniel N., et al.
Publicado: (2020)

Cuteness engineering: designing adorable products and services
por: Marcus, Aaron, et al.
Publicado: (2017)

Will we cure cancer by sequencing thousands of genomes?
por: Nicholson, Joshua M
Publicado: (2013)

Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
por: Patel, Shruti R., et al.
Publicado: (2023)

Diaphragmatic hernia during treatment of lung cancer harboring an EGFR mutation
por: Konno-Yamamoto, Aya, et al.
Publicado: (2021)

ADAURA, a Bridge Connecting Disease Control with Long-term Survival
por: Zhao, Jing, et al.
Publicado: (2021)

The management of postoperative recurrence of non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutation: what is the best way?
por: Adachi, Hiroyuki, et al.
Publicado: (2022)

Mutant Proteomics of Lung Adenocarcinomas Harboring Different EGFR Mutations
por: Nishimura, Toshihide, et al.
Publicado: (2020)

HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer
por: Yamaoka, Toshimitsu, et al.
Publicado: (2020)

Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC
por: Brazel, Danielle, et al.
Publicado: (2022)

Co-mutations in EGFR driven non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2019)

Relations of admiration and adoration with other emotions and well-being
por: Schindler, Ines
Publicado: (2014)

The adoration of a map: Reflections on a genome metaphor
por: Zwart, Hub
Publicado: (2009)

Image of China in Slovakia: ambivalence, adoration, and fake news
por: Šimalčík, Matej
Publicado: (2021)

Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs
por: Melosky, Barbara, et al.
Publicado: (2014)

First-line management of advanced non-small-cell lung cancer: can we do better?
por: Chouaïd, Christos, et al.
Publicado: (2023)

To combine or not to combine: anti-vascular endothelial growth factor therapies in EGFR mutation positive non-small cell lung cancer
por: Horinouchi, Hidehito
Publicado: (2020)

Neoadjuvant therapy in localized non-small cell lung cancer: can we do better than chemotherapy?
por: Chau, Brittney, et al.
Publicado: (2019)

Different perspectives and viewpoints on the postoperative management of EGFR-mutant lung cancer
por: Nakao, Masayuki, et al.
Publicado: (2020)

EGFR and non-small cell lung cancer: implications for surgical practice
por: Varela, Gonzalo, et al.
Publicado: (2020)

Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation
por: Morichika, Daisuke, et al.
Publicado: (2016)

Growth Suppression in Lung Cancer Cells Harboring EGFR-C797S Mutation by Quercetin
por: Huang, Kuo-Yen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jtisq4orrgugpjn8bborondfge